Link Pharma Chem Ltd (LINKPH) — shareholding pattern, promoter holding, financials and share price
About Link Pharma Chem Ltd (LINKPH)
Link Pharma Chem Ltd operates in the Commodity Chemicals industry, within the Chemicals sector. It trades on the NSE as LINKPH and on the BSE under scrip code 524748. Its ISIN is INE302F01011.
Incorporated in 1986, Link Pharma Chem Ltd is in the business of manufacturing and job work of organic intermediate [1]
Link Pharma Chem Ltd is a mid-sized chemical manufacturing company founded in 1986, specializing in thionyl chloride and other chemical intermediates for pharmaceutical, agro-industrial, and specialty chemical applications.
The company has a robust capacity for carrying out corrosive chemical reactions, equipped with advanced reactor technologies to meet diverse industry needs.
Listed peers in Commodity Chemicals: Omkar Pharmachem Ltd, Sreechem Resins Ltd, Emmessar Biotech & Nutrition Ltd, Kuwer Industries Ltd, Lime Chemicals Ltd, Bhagawati Oxygen Ltd.
Valuation & Returns
10 Jul 2026At ₹26.78 a share on 10 Jul 2026, Link Pharma Chem Ltd (LINKPH) was valued at a price-to-earnings ratio of 148.59x against an industry P/E of 45.11x and a price-to-book of 0.94x on a book value of ₹28.51 per share as of Mar 2025. Solomo computes return on equity of 0.63% and return on capital employed of 3.52% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 148.59x
- Industry P/E
- 45.11x
- P/B
- 0.94x
- EPS (TTM)
- ₹0.18
- Book value / share
- ₹28.51
- ROE
- 0.63%
- ROCE
- 3.52%
- ROA
- 0.34%
- Debt / equity
- 0.46x
- Dividend yield
- 0%
- EBITDA margin
- 6.02%
- 52-week range
- ₹21 – ₹41.9
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Link Pharma Chem Ltd (LINKPH) reported revenue of ₹27.43 crore, net profit of ₹0.08 crore and earnings per share of ₹0.18. That compares with revenue of ₹25.43 crore and net profit of ₹-1.03 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹6.59 crore and net profit ₹-0.41 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 53.56 | 38.76 | 29.9 | 25.43 | 27.43 |
| Net profit (₹ cr) | 1.88 | 0.65 | -1.36 | -1.03 | 0.08 |
| EPS (₹) | 4.23 | 1.46 | -3.06 | -2.32 | 0.18 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 7.42% | -0.03% | -21.98% | -14.95% |
| Profit growth | - | - | - | 24.26% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 52.4% of Link Pharma Chem Ltd (LINKPH) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.02%. Market capitalisation was ₹12 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Gurudev Marketing Pvt. Ltd. 5.76%, HUF 2.64%, Daksha Vishanji Kotak 1.87%, Chirayu Jayesh Shah (Huf) 1.2%, Thakorbhai Vinubhai Mistry 1.18%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 52.4% | - | - | 0.02% | 47.6% |
| Mar 2026 | 52.4% | - | - | 0.02% | 47.6% |
| Dec 2025 | 51.49% | - | - | 0.02% | 48.51% |
| Sep 2025 | 51.49% | - | - | 0.02% | 48.51% |
| Jun 2025 | 51.49% | - | - | 0.02% | 48.51% |
| Mar 2025 | 51.49% | - | - | 0.02% | 48.51% |
| Dec 2024 | 51.49% | - | - | 0.02% | 48.51% |
| Sep 2024 | 51.49% | - | - | 0.02% | 48.51% |